The Clinical Trials Network (CTN) of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) operates a PET/CT phantom imaging program using the CTN's oncology clinical simulator phantom, designed to validate scanners at sites that wish to participate in oncology clinical trials. Since its inception in 2008, the CTN has collected 406 well-characterized phantom datasets from 237 scanners at 170 imaging sites covering the spectrum of commercially available PET/CT systems. The combined and collated phantom data describe a global profile of quantitative performance and variability of PET/CT data used in both clinical practice and clinical trials. Methods: Individual sites filled and imaged the CTN oncology PET phantom according to detailed instructions. Standard clinical reconstructions were requested and submitted. The phantom itself contains uniform regions suitable for scanner calibration assessment, lung fields, and 6 hot spheric lesions with diameters ranging from 7 to 20 mm at a 4:1 contrast ratio with primary background. The CTN Phantom Imaging Core evaluated the quality of the phantom fill and imaging and measured background standardized uptake values to assess scanner calibration and maximum standardized uptake values of all 6 lesions to review quantitative performance. Scanner make-and-modelspecific measurements were pooled and then subdivided by reconstruction to create scanner-specific quantitative profiles. Results: Different makes and models of scanners predictably demonstrated different quantitative performance profiles including, in some cases, small calibration bias. Differences in site-specific reconstruction parameters increased the quantitative variability among similar scanners, with postreconstruction smoothing filters being the most influential parameter. Quantitative assessment of this intrascanner variability over this large collection of phantom data gives, for the first time, estimates of reconstruction variance introduced into trials from allowing trial sites to use their preferred reconstruction methodologies. Predictably, time-of-flight-enabled scanners exhibited less size-based partialvolume bias than non-time-of-flight scanners. Conclusion: The CTN scanner validation experience over the past 5 y has generated a rich, well-curated phantom dataset from which PET/CT make-and-model and reconstruction-dependent quantitative behaviors were characterized for the purposes of understanding and estimating scanner-based variances in clinical trials. These results should make it possible to identify and recommend make-and-model-specific reconstruction strategies to minimize measurement variability in cancer clinical trials. Mul ticenter oncology clinical trials are increasingly using PET/CT imaging as primary and secondary endpoints to define success or failure of treatment regimens, with considerable effort expended in understanding reproducibility and variability (1-11). PET, as an inherently quantitative imaging technique, is arguably the most powerful imaging modality available to researchers to assess response to therapy in the multicenter clinical trial setting. However, the accurate and reproducible quantitation methodology necessary to successfully complete a trial involving quantitative PET imaging has been complicated by vendors of commercial PET/CT scanner systems that understandably strive to generate higher quality diagnostic images to achieve market differentiation. Although these efforts advance the field, they also paradoxically add variability to multicenter trials that include PET/CT equipment whose inherent hardware and software technologies can differ by more than a decade. The introduction of time-of-flight (TOF)-capable scanners and reconstruction advancements including iterative approaches that account for the position-sensitive point-response function have further increased both quantitative and qualitative differences between older-and newer-generation scanners. The divergent image quality and varying quantitation make comparison of quantitative data associated with different makes and models of scanners of different vintages problematic within the context of multicenter clinical trials seeking to use metrics such as standardized uptake values (SUVs) and total lesion glycolysis (1,12).
The Clinical Trials Network (CTN) of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) operates a PET/CT phantom imaging program using the CTN's oncology clinical simulator phantom, designed to validate scanners at sites that wish to participate in oncology clinical trials. Since its inception in 2008, the CTN has collected 406 well-characterized phantom datasets from 237 scanners at 170 imaging sites covering the spectrum of commercially available PET/CT systems. The combined and collated phantom data describe a global profile of quantitative performance and variability of PET/CT data used in both clinical practice and clinical trials. Methods: Individual sites filled and imaged the CTN oncology PET phantom according to detailed instructions. Standard clinical reconstructions were requested and submitted. The phantom itself contains uniform regions suitable for scanner calibration assessment, lung fields, and 6 hot spheric lesions with diameters ranging from 7 to 20 mm at a 4:1 contrast ratio with primary background. The CTN Phantom Imaging Core evaluated the quality of the phantom fill and imaging and measured background standardized uptake values to assess scanner calibration and maximum standardized uptake values of all 6 lesions to review quantitative performance. Scanner make-and-modelspecific measurements were pooled and then subdivided by reconstruction to create scanner-specific quantitative profiles. Results: Different makes and models of scanners predictably demonstrated different quantitative performance profiles including, in some cases, small calibration bias. Differences in site-specific reconstruction parameters increased the quantitative variability among similar scanners, with postreconstruction smoothing filters being the most influential parameter. Quantitative assessment of this intrascanner variability over this large collection of phantom data gives, for the first time, estimates of reconstruction variance introduced into trials from allowing trial sites to use their preferred reconstruction methodologies. Predictably, time-of-flight-enabled scanners exhibited less size-based partialvolume bias than non-time-of-flight scanners. Conclusion: The CTN scanner validation experience over the past 5 y has generated a rich, well-curated phantom dataset from which PET/CT make-and-model and reconstruction-dependent quantitative behaviors were characterized for the purposes of understanding and estimating scanner-based variances in clinical trials. These results should make it possible to identify and recommend make-and-model-specific reconstruction strategies to minimize measurement variability in cancer clinical trials. Mul ticenter oncology clinical trials are increasingly using PET/CT imaging as primary and secondary endpoints to define success or failure of treatment regimens, with considerable effort expended in understanding reproducibility and variability (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . PET, as an inherently quantitative imaging technique, is arguably the most powerful imaging modality available to researchers to assess response to therapy in the multicenter clinical trial setting. However, the accurate and reproducible quantitation methodology necessary to successfully complete a trial involving quantitative PET imaging has been complicated by vendors of commercial PET/CT scanner systems that understandably strive to generate higher quality diagnostic images to achieve market differentiation. Although these efforts advance the field, they also paradoxically add variability to multicenter trials that include PET/CT equipment whose inherent hardware and software technologies can differ by more than a decade. The introduction of time-of-flight (TOF)-capable scanners and reconstruction advancements including iterative approaches that account for the position-sensitive point-response function have further increased both quantitative and qualitative differences between older-and newer-generation scanners. The divergent image quality and varying quantitation make comparison of quantitative data associated with different makes and models of scanners of different vintages problematic within the context of multicenter clinical trials seeking to use metrics such as standardized uptake values (SUVs) and total lesion glycolysis (1, 12) .
Several professional societies have initiated programs and are devising and promoting standardization practices designed to reduce variability within the context of image quantitation in clinical trials. Organizations such as the American College of Radiology Imaging Network (ACRIN), The Radiologic Society of North America's Quantitative Imaging Biomarker Alliance, the American Association of Physicists in Medicine, the European Association of Nuclear Medicine's Research 4 Life, and the Society of Nuclear Medicine and Molecular Imaging (SNMMI), both alone and together, have made significant strides in this area. Several of these organizations administer PET/CT phantom imaging programs to aid in the standardization of quantitation in clinical trials and clinical practice (13) (14) (15) (16) . These programs are separate and distinct from clinical accreditations such as those administered by the American College of Radiology and the Intersocietal Accreditation Commission as well as the Joint Commission.
In September 2008, the Clinical Trials Network (CTN) was created by SNMMI. The mission of the CTN is to advance the use of molecular imaging radiopharmaceuticals in clinical trials through standardization of chemistry and imaging methodology. This includes using imaging radiopharmaceuticals during the course of drug development and bringing new radiopharmaceuticals to regulatory approval. The CTN operates a phantom-based validation program for PET/CT scanners that uses a unique anthropomorphic chest phantom specifically for validating the quantitative performance of PET/CT scanners for use in oncology clinical trials.
From its inception through January 2014, the CTN has gathered and analyzed more than 400 phantom datasets collected from 237 unique PET/CT scanners acquired from a diverse group of 170 international imaging centers. These centers run the gamut from community-based imaging centers to academic sites. Virtually all makes and models of scanners from the last decade are represented in the datasets. Specifically excluded from the oncology phantom data are those collected from mobile PET/CT systems and PET-only systems. The image data from scanners that passed the validation criteria in these phantom studies form the basis of the analysis presented here.
The study includes PET/CT scanners with technology advancements spanning more than a decade. Reconstruction methods have also evolved substantially during this period. GE Healthcare and Siemens PET/CT systems have historically used similar iterative reconstructions, giving users a broad level of flexibility in determining their own level of convergence by specifying their preferred number of updates (iterations and subsets) and also allowing the ability to apply postreconstruction gaussian smoothing filters of user-defined width. Reconstructions with Philips scanners, although also iterative, allow the user less latitude in reconstruction and do not provide the ability to filter the images after reconstruction.
The overall goal of this analysis was to assess quantitative variability of PET data in the context of single-site and multicenter clinical trials that is introduced specifically by variability in scanner calibration and quantitative maximum SUV (SUV max ) measurement of spheric tumorlike lesions in the CTN oncology phantom. By better understanding the magnitude and sources of these variances, the field should be able to devise strategies to predictably enhance the quality of quantitative PET imaging data for clinical trials.
MATERIALS AND METHODS

Phantom Imaging and Data Collection
The CTN oncology clinical simulator phantom is an anthropomorphic chest phantom with lung fields and 6 spheric objects with inner diameters ranging from 7 to 20 mm reproducibly secured at specific locations within the phantom (Fig. 1) (16,17) . The 6 spheres are serially connected via narrow-bore tubing allowing a single syringe to fill all 6 spheres. The phantom has a single 7-mm-diameter sphere located in the mediastinum, two 10-mm spheres placed in the lung fields, a 10-mm sphere in an area corresponding to an axillary lymph node, a single 15-mmdiameter sphere in the left shoulder, and a single 20-mm-diameter sphere in the right lung field. The nominal concentration of the spheres and background at phantom imaging times are 24.0 and 6.0 kBq/mL, respectively, resulting in a 4:1 lesion-to-background concentration ratio with scanning commencing precisely 60 min after assay of the fill syringes. These concentrations were designed to simulate clinically relevant concentrations and contrasts found in 18 F-FDG PET oncology imaging. Phantom imaging was performed for 4 min per bed position for 3-dimensional imaging and 6 min per bed position for 2-dimensional imaging. The sites were instructed to use their standard low-dose attenuation-correction CT protocol and to reconstruct the images using their standard clinical reconstruction parameter set. However, the sites were also instructed not to implement point-response-function-assisted reconstructions because of variability of reconstructed quantitation using these techniques at this time. A predetermined patient weight (63 kg) and injected dose (555 MBq) were designed to produce a background SUV of 1.00 if the prescribed fill instructions were followed.
For validation purposes, each site submitted the attenuationcorrected PET scans, non-attenuation-corrected PET scans, and CT scans used for attenuation correction to the CTN Phantom Imaging Core. The phantom-fill data (activities and times), as well as PET and CT acquisition and reconstruction parameters and general information regarding the scanner, were submitted on paper.
The Scanner Validation Core Lab performed a series of quality control steps before final quantitative analysis using Siemens syngo. via (va20), Siemens Inveon Research Workstation (IRW; version 4.2), and OsiriX (Pixmeo SARL; version 5.9). The PET/CT datasets were overlaid using the above software to assess the accuracy of the PET/CT registration for the scanner by comparing the 3-dimensional position of each of the 6 spheres on the CT scan with their location on the PET scan. Misregistrations on the order of 3 mm in any dimension were visually detectable. The CT scan was carefully checked for the existence of air bubbles in the spheric lesions, because this will cause anomalously low SUV readings. An incomplete fill resulted in a request for the site to refill and rescan the phantom.
The sites were also asked to make both an SUV max measurement of all identified lesions and a background measurement in the right shoulder region for assessment of scanner calibration accuracy. The CTN Scanner Validation Core Lab subsequently made its own measurements of the SUV max for the spheric lesions and mean SUV (SUV mean ) for the background. The Core Lab measurements are those reported in this article.
The acceptance criterion for the SUV mean of the background region was set at 1.0 6 0.1. This criterion 610% permissible variability is consistent with criteria of most other organizations that are currently addressing limits for acceptable quantitative PET scanner calibration performance for clinical trials (2, (13) (14) (15) 18) . Because spheres of different sizes are placed within the phantom in different background settings, and scanner-specific performance in this complex environment was originally unknown, rigid sphere-specific acceptance criteria for SUV max for the various sphere sizes are currently not strictly set. The current work presented here will act as the basis for these acceptance criteria moving forward.
Phantom Analysis Approach
For the purposes of analysis and data reduction, scanner models from a particular vendor whose PET imaging properties were generally equivalent were bundled together. Fourteen distinct scanner groups were ultimately identified and are listed in Table 1 . The proportion of GE Healthcare, Siemens, and Philips scanners in this sample make up approximately 56%, 34%, and 10% of the scanners, respectively.
For this analysis, the phantom data collected were analyzed in 2 general areas: overall scanner calibration and scanner-and reconstructionspecific lesion quantitation.
The analysis of the reconstruction parameter sets (iterations, subsets, gaussian filter width) of the more than 240 PET/CT scanners revealed more than 100 different reconstruction parameter sets being used from the imaging sites in the database, demonstrating a substantial lack of standardization. Supplemental Table 1 (supplemental materials are available at http://jnm.snmjournals.org) details the reconstruction parameter sets and the frequency distribution per scanner. The database and data collection were not initially configured to collect Philips-specific parameters and are therefore not reported in the supplemental table.
Scanner Validation Core Lab analysis was performed using Siemens syngo.via workstations, Siemens IRW, and OsiriX. All workstations were verified to generate the same SUV max generally to within 2% of one another; however, not all workstations were capable of generating SUV measurements from all scanner system image sets. OsiriX proved most universally capable of quantitation of concentration and SUVs and was used in those cases in which the other workstations failed to generate quantitative information.
Scanner Calibration Analysis
For scanner calibration assessment, an approximately 30-mm-diameter spheric volume of interest (VOI) was created in the right shoulder, which was a uniform region devoid of complicating structures and concentrations. The region was placed far from the edges of the phantom to avoid partial-volume effects. The mean and SD of the VOI were recorded. The calibration data from similar models as described in Table 1 were pooled to assess scanner model-specific trends. Two-sided t test analysis was performed to determine whether the individual scannerspecific background distributions were statistically significantly different from the parent background distribution of all scanners combined. An additional spheric VOI was placed in the uniform region located caudally in the phantom in the area near where the myocardium would be anatomically located (the myocardial background region). The difference between the right shoulder background SUV mean and the background myocardial SUV mean was calculated for all scanner studies. Results were compiled for each make and model of scanner to determine whether scanner-specific quantitative anatomic biases exist.
Reconstruction-Specific Quantitation
For the scanner-and reconstruction-specific lesion quantitation analysis, spheric VOIs with diameters at least 2 times the diameter of the actual spheres were drawn over all 6 spheric objects. CT information was used when the precise location of the lesion was not apparent on the PET scan. SUV max measurements were made for each of the lesions. Both the imaging site and the Scanner Validation Core Lab made this measurement. The Core measurements are those presented. For the purposes of this analysis, only the SUV max measurements from the 5 spheres 10 mm and larger are reported. They were first combined by scanner model and then subsequently subcategorized by reconstruction. Measurements of the 7-mm sphere were specifically excluded from this analysis because so few scanners were able to detect it. Subcategorization was performed by the width of the gaussian reconstruction filter used, because this was determined to have the most significant quantitative impact. To achieve meaningful statistical numbers of phantom scans, gaussian filter width ranges were typically used, rather than a specific filter width. Because Philips scanner reconstructions do not provide the ability to choose a postreconstruction filter, Philips phantom data were analyzed per scanner but not subsequently subcategorized.
RESULTS
Scanner Calibration
The assessment of accuracy of scanner calibration was performed on all submitted phantom studies by creating a spheric VOI in the uniform region of the left shoulder as described above. The SUV mean was calculated for each attenuation-corrected phantom study, and the results were tabulated into frequency histograms for all 14 scanner models. Representative SUV mean histogram distributions for background measurements (nominally 5 1.00) for 2 PET/CT scanner models are presented in Figures 2A and 2B . The mean and SD calculated for each of the 14 scanner models are shown in Figure 2C .
All pooled model-specific mean background values (Fig. 2C ) are within 64% of the actual concentration. However, the Discovery 690-710 scanners (GE Healthcare) and the Biograph 2-6 scanners (Siemens) both demonstrated a statistically significant positive bias when compared with the parent background SUV distribution. Four other scanner models (annotated in Fig. 2C ) had P values between 0.05 and 0.1, suggesting the possibility of slight bias.
Scanner-specific differences between shoulder background SUV mean and the background myocardial SUV mean are listed in Tables 2 and 3 . In nearly half of the 14 scanner models investigated, there was a clear reconstruction-driven bias between the measurements in the shoulder region and the myocardial region. Investigating the GE Healthcare line of PET/CT scanners gives insight into these phenomena. In 10 of 11 phantom scans with the 600 PET/CT scanner (GE Healthcare), the myocardial background region concentration measurement was greater than that in the shoulder region. However, with the 690-710 scanners (GE Healthcare), the opposite was found, with 31 of 33 scans having the shoulder region greater than the myocardial region. GE Healthcare's older models (the ST and STE) demonstrated no such bias.
Lesion Quantitation
Although updates (defined as iterations · subsets) affect quantitation, categorizing individual scanner data by the postreconstruction gaussian filter width demonstrated the most significant and systematic quantitative impact and is the basis of the data and analysis presented. The reconstructions for each of the PET/CT scanner models (Table 1) were sorted and pooled by gaussian filter width. The complete set of data for the 14 scanner models is presented in Table 4 . Representative results of the SUV max for each of the 5 spheres 10 mm and larger for the Discovery STE and Discovery 690-710 (GE Healthcare), Biograph TruePoint (Siemens), and TF (Philips) are graphically presented in Figure 3 . All results for individual scanner models are presented in histogram plots in Supplemental Figures 1-3 . In each of these histogram plots, the leftmost bar is the mean SUV max for that sphere for the entire 406 phantom datasets. Subsequent bars represent mean SUV max for increasing gaussian filter width ranges used in reconstructions for that model scanner. Three filter bin widths were typically selected for each of the scanner models primarily to balance, to the extent possible, the number of phantom scans in each bin. However, balanced distribution was often not possible. Philips, as previously mentioned, does not allow the user the capability to filter the image after reconstruction. Given the limited number of scanners per model in our sample, refining filter bin widths beyond 3 bins would have resulted in too little data per bin for conclusions to be drawn.
Differences in general quantitative performance between vendors was not observed; however, the vintage of scanner models did appear to affect the range and distribution of measured SUV max for the spheres. For the purposes of this analysis, early-generation PET/CT scanners (Discovery LS, Biograph Duo and Biograph 6, and Gemini and Gemini GS [Philips]) were bundled into 1 category, recent higher performance TOF scanners (690-710, mCT [Siemens] , and Ingenuity [Philips]) were put into a second category, and the remaining PET/CT scanners were segregated into a third mid-range performance category. Examples of the different SUV max distributions for these 3 categories for the 15-mm left shoulder sphere and the 10-mm right lung sphere are shown in Figures 4A and 4B . Virtually all of the anomalously high SUV max in the plots in the high-performance TOF scanner distribution are associated with point-response-function reconstructions that were inadvertently submitted to CTN (CTN specifically excludes point-response-function reconstructions from its official analyses). The inclusion of these data in these plots is to demonstrate the broad and largely unpredictable quantitative behavior of these reconstructions with current implementations.
DISCUSSION
Multicenter clinical trials typically, and sometimes necessarily, recruit a cross-section of medical centers that range from community-based clinics to world-class academic centers. Imaging sites at these institutions use a range of scanners of different make and model, and the trial protocol generally asks the sites to image their study subjects using their standard clinical acquisition and reconstruction. The impact of this uncontrolled approach to imaging on any quantitative endpoint within the context of a multicenter clinical trial is largely unknown. However, it is clear that any additional variance that results from quantitative variability across imaging equipment and technique will detrimentally affect the statistical power of the study and require more subjects at significantly greater expense. The collection of more than 400 CTN oncology phantom datasets is a rich and diverse set of qualitative and quantitative information on scanner performance across site type, scanner make and model, and vintage. The data presented provide the first, to our knowledge, large-scale controlled systematic analysis of the impact of scanner and reconstruction-specific quantitative performance.
Perhaps the most surprising result of the phantom dataset is the diversity of reconstruction parameter sets even when limited to a single scanner model. Each scanner site typically begins with a default reconstruction parameter set but then experiments with different parameter sets to achieve a clinical image quality with which the particular site physicians are comfortable. Vendors understandably are providing both the means and the opportunity for each site to optimize reconstructions to their own preferences. However, means and opportunity create an environment where quantitative variability will be inevitable in any multicenter trial.
Scanner Calibration
By convention, all PET scanners are calibrated with a 20-cmdiameter cylindric phantom with known concentration. The accuracy of this calibration is tied to the accuracy of the dose calibrator, timing, and volume measurements associated with the calibration procedure. A properly calibrated scanner will demonstrate accurate concentration measurements in the cylindric phantom across the entire axial field of view, which is precisely what the ACRIN phantom procedure measures and verifies. The CTN oncology phantom is neither designed to nor capable of confirming full axial field-of-view calibration. Because the VOI for background measurement in the anthropomorphic chest phantom is in the right shoulder, far from the center of the scanner field of view, and because of phantom asymmetry, there is the possibility for calibration measurement bias as compared with that obtained from a standard 20-cm-diameter cylindric phantom. The background SUV distributions for each of the 3 TOF systems from the 3 vendors each demonstrated a nonstatistically significant, but suggestive, calibration bias as measured in the shoulder area of the phantom. These biases, if real, may result from scatter corrections tuned to standard simple geometries that may be rendered inaccurate under more complex situations.
The hypothesis that the complexity of the phantom presents a more significant quantitative challenge is supported by additional background measurements that were made in the uniform myocardial region of the phantom. Specific scanner models frequently showed significant differences between the shoulder background and myocardial background measurements. These differences are not evident in the more common ACRIN-style cylindric phantom test of scanner uniformity. ACRIN's own observation of differences in mean liver SUV between vendors supports the existence of this problem (13) .
Current scatter-correction assessments, such as in National Electrical Manufacturers Association (NEMA) measurements or with the NEMA image quality phantom, are made closer to the center of the scanner field of view and have a uniform concentration and density. The CTN oncology phantom is complex in design and geometry, with multiple-density internal objects, and therefore presents a different and more challenging imaging scenario.
Benchmarking
One of the primary uses of the current CTN oncology phantom image and reconstruction database is benchmarking. An individual scanner can be quantitatively benchmarked against itself, based on prescribed periodic phantom imaging during the course of a clinical trial to determine long-term quantitative stability and variance. Additionally, a particular scanner's performance can be benchmarked against both identical scanners that use different reconstructions and also identical scanners with virtually identical reconstructions. In either case, an individual phantom scan result, when compared with the compiled and categorized data, can inform the site and trial sponsor of a scanner's performance relative to relevant statistical parent distributions.
With these data, it is also possible for a trial sponsor to estimate an anticipated variance of quantitative data based on the mix of scanner makes and models used in a multicenter trial (with associated reconstructions) using the compiled SUV max database for the phantom. For trial sponsors interested in more prospectively harmonized quantitative data, the database can help sponsors identify make-andmodel-specific candidate reconstructions that might help reduce variances prospectively. Because current TOF-enabled scanners demonstrated significantly higher quantitative performance (higher SUV max ) than those without TOF capabilities (Figs. 4A and 4B ), a sponsor might consider requiring TOF scanners to reconstruct without the TOF information to reduce differences between scanners. Alternatively, excluding earlier vintage scanners from multicenter clinical trials may be a reasonable strategy for trials in which absolute quantitative measurements are critical.
Quantitative scanner performance as defined by SUV max of the spheres in the CTN phantom demonstrated significant variability, which was not unexpected given the broad range of scanner vintages and the diversity of reconstructions. Categorizing SUV max results by scanner and subcategorizing by postreconstruction gaussian filter width demonstrated expected reduction of SUV max with increasing filter width for all spheres and all scanner makes and models. Within a given model, this decrease in SUV max occurred at a rate of approximately 0.2-0.3 SUV units per additional millimeter of filter width.
CONCLUSION
The current assembly of more than 400 CTN oncology phantom scans includes multiple image sets from virtually all makes and models of PET/CT scanners. The CTN oncology phantom demonstrated utility in both validating scanner calibration and characterizing the reconstruction-specific quantitative imaging characteristics of 14 different makes and models of PET/CT scanners through the measurement of SUV max for the phantom's 5 spheric objects (10-20 mm). The analysis of the variability in the reported phantom lesion measurements should enable sponsors and designers of clinical trials to better estimate quantitative variance within a multicenter clinical trial setting. The reconstruction-specific data should also be useful to help trial designers minimize variance by selecting scanner-specific reconstructions toward quantitative harmonization.
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